Literature DB >> 30606808

BCL6 inhibition: a chronic GVHD twofer.

Paola Vinci1, Alan M Hanash1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30606808      PMCID： PMC6318425          DOI： 10.1182/blood-2018-11-879692

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Christopher J Fraser; Smita Bhatia; Kirsten Ness; Andrea Carter; Liton Francisco; Mukta Arora; Pablo Parker; Stephen Forman; Daniel Weisdorf; James G Gurney; K Scott Baker
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

2.  Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

Authors:  David Miklos; Corey S Cutler; Mukta Arora; Edmund K Waller; Madan Jagasia; Iskra Pusic; Mary E Flowers; Aaron C Logan; Ryotaro Nakamura; Bruce R Blazar; Yunfeng Li; Stephen Chang; Indu Lal; Jason Dubovsky; Danelle F James; Lori Styles; Samantha Jaglowski
Journal:  Blood       Date:  2017-09-18       Impact factor: 22.113

Review 3.  Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis.

Authors:  Mohamed A Kharfan-Dabaja; Asmita R Mhaskar; Benjamin Djulbegovic; Corey Cutler; Mohamad Mohty; Ambuj Kumar
Journal:  Biol Blood Marrow Transplant       Date:  2009-06-10       Impact factor: 5.742

4.  Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.

Authors:  Scott R Solomon; Connie A Sizemore; Michelle Ridgeway; Xu Zhang; Judith Smith; Stacey Brown; H Kent Holland; Lawrence E Morris; Asad Bashey
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-16       Impact factor: 5.742

5.  Disruption of the Bcl6 gene results in an impaired germinal center formation.

Authors:  T Fukuda; T Yoshida; S Okada; M Hatano; T Miki; K Ishibashi; S Okabe; H Koseki; S Hirosawa; M Taniguchi; N Miyasaka; T Tokuhisa
Journal:  J Exp Med       Date:  1997-08-04       Impact factor: 14.307

6.  Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study.

Authors:  Florent Malard; Myriam Labopin; Ibrahim Yakoub-Agha; Sylvain Chantepie; Thierry Guillaume; Didier Blaise; Reza Tabrizi; Leonardo Magro; Bernard Vanhove; Gilles Blancho; Philippe Moreau; Béatrice Gaugler; Patrice Chevallier; Mohamad Mohty
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

7.  Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.

Authors:  Katelyn Paz; Ryan Flynn; Jing Du; Jun Qi; Leo Luznik; Ivan Maillard; Kelli P MacDonald; Geoffrey R Hill; Jonathan S Serody; William J Murphy; Peter T Sage; Arlene H Sharpe; David Miklos; Corey S Cutler; John Koreth; Joseph H Antin; Robert J Soiffer; Jerome Ritz; James E Bradner; Ari M Melnick; Bruce R Blazar
Journal:  Blood       Date:  2018-10-02       Impact factor: 22.113

8.  Bcl6 mediates the development of T follicular helper cells.

Authors:  Roza I Nurieva; Yeonseok Chung; Gustavo J Martinez; Xuexian O Yang; Shinya Tanaka; Tatyana D Matskevitch; Yi-Hong Wang; Chen Dong
Journal:  Science       Date:  2009-07-23       Impact factor: 47.728

Review 9.  Classification systems for chronic graft-versus-host disease.

Authors:  Stephanie J Lee
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

10.  Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.

Authors:  Ryan Flynn; Jing Du; Rachelle G Veenstra; Dawn K Reichenbach; Angela Panoskaltsis-Mortari; Patricia A Taylor; Gordon J Freeman; Jonathan S Serody; William J Murphy; David H Munn; Stefanie Sarantopoulos; Leo Luznik; Ivan Maillard; John Koreth; Corey Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Jason A Dubovsky; John C Byrd; Kelli P MacDonald; Geoff R Hill; Bruce R Blazar
Journal:  Blood       Date:  2014-05-12       Impact factor: 22.113
  10 in total
  1 in total

1.  BCL6 BTB-specific inhibitor reversely represses T-cell activation, Tfh cells differentiation, and germinal center reaction in vivo.

Authors:  Yanhui Cai; Adi Narayana Reddy Poli; Surya Vadrevu; Kwasi Gyampoh; Colin Hart; Brian Ross; Matt Fair; Fengtian Xue; Joseph M Salvino; Luis J Montaner
Journal:  Eur J Immunol       Date:  2021-09-16       Impact factor: 5.532
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.